These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 19671394

  • 1. [Hypertension and the heart].
    Wachtell K, Andersen NH, Svendsen TL.
    Ugeskr Laeger; 2009 Jun 15; 171(25):2113-6. PubMed ID: 19671394
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):705-11. PubMed ID: 15734614
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB.
    J Am Coll Cardiol; 2005 Mar 01; 45(5):712-9. PubMed ID: 15734615
    [Abstract] [Full Text] [Related]

  • 4. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.
    Circ Arrhythm Electrophysiol; 2008 Dec 01; 1(5):337-43. PubMed ID: 19808428
    [Abstract] [Full Text] [Related]

  • 5. [Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
    Baumgart P.
    MMW Fortschr Med; 2006 Mar 16; 148(11):57, 59-60. PubMed ID: 16612965
    [No Abstract] [Full Text] [Related]

  • 6. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB, Dahlöf B.
    Curr Med Res Opin; 2007 Feb 16; 23(2):443-57. PubMed ID: 17288698
    [Abstract] [Full Text] [Related]

  • 7. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA, Flaa A, Strand A, Kjeldsen SE.
    J Hypertens; 2007 Jan 16; 25(1):15-23. PubMed ID: 17143167
    [Abstract] [Full Text] [Related]

  • 8. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J.
    Clin Ther; 2006 Jun 16; 28(6):832-48. PubMed ID: 16860167
    [Abstract] [Full Text] [Related]

  • 9. Hypertensive heart disease--significance of left ventricular hypertrophy.
    Schmieder RE.
    J Cardiovasc Pharmacol; 1992 Jun 16; 20 Suppl 6():S50-5. PubMed ID: 1283190
    [Abstract] [Full Text] [Related]

  • 10. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
    Krauser DG, Devereux RB.
    Herz; 2006 Jun 16; 31(4):305-16. PubMed ID: 16810470
    [Abstract] [Full Text] [Related]

  • 11. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 16; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 12. The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.
    Wachtell K, Devereux RB, Lyle PA, Okin PM, Gerdts E.
    Ther Adv Cardiovasc Dis; 2008 Dec 16; 2(6):507-13. PubMed ID: 19124445
    [Abstract] [Full Text] [Related]

  • 13. Slower heart rates for healthy hearts: time to redefine tachycardia?
    Gopinathannair R, Sullivan RM, Olshansky B.
    Circ Arrhythm Electrophysiol; 2008 Dec 16; 1(5):321-3. PubMed ID: 19808425
    [No Abstract] [Full Text] [Related]

  • 14. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E, Muiesan ML, Rizzoni D.
    Ann Ital Med Int; 1993 Oct 16; 8 Suppl():97S-103S. PubMed ID: 8117529
    [Abstract] [Full Text] [Related]

  • 15. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM, Schmieder RE.
    Am J Hypertens; 2008 May 16; 21(5):500-8. PubMed ID: 18437140
    [Abstract] [Full Text] [Related]

  • 16. [Atrial fibrillation as end point of hypertension. Can antihypertensive therapy prevent it?].
    Geller JC.
    MMW Fortschr Med; 2003 Nov 20; 145(47):38-41. PubMed ID: 14725032
    [Abstract] [Full Text] [Related]

  • 17. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
    MMW Fortschr Med; 2006 Mar 30; 148(13):48-9. PubMed ID: 16642707
    [No Abstract] [Full Text] [Related]

  • 18. Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke.
    Subramaniam V, Lip GY.
    Expert Rev Cardiovasc Ther; 2009 Jun 30; 7(6):703-13. PubMed ID: 19505285
    [Abstract] [Full Text] [Related]

  • 19. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z, Dahlöf B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H, Nieminen MS, Jern S, Devereux RB.
    J Hypertens; 2008 Jun 30; 26(6):1244-9. PubMed ID: 18475164
    [Abstract] [Full Text] [Related]

  • 20. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
    Bang CN, Okin PM, Køber L, Wachtell K, Gottlieb AB, Devereux RB.
    J Hypertens; 2014 Mar 30; 32(3):667-72. PubMed ID: 24379001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.